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Nephrotoxicity induced by cisplatin involves tubular cell
necrosis and apoptosis; the latter of which may be initiated
by multiple mechanisms including activation of the intrinsic
mitochondrial pathway. In cultured tubular epithelial cells,
cisplatin can activate the proapoptotic protein Bax resulting
in cytochrome c release, caspase activation, and apoptosis.
Definitive evidence for the involvement of Bax in cisplatin
nephrotoxicity in vivo, however, is lacking. We analyzed Bax
regulation during cisplatin nephrotoxicity in wild-type mice
and determined the pathological role of Bax using mice in
which this gene was knocked out. In wild-type mice, cisplatin
induced Bax in renal tubular cells which became active,
accumulated in the mitochondria, and was accompanied by
acute kidney injury. Compared with the wild-type mice renal
function, as measured by blood urea nitrogen and serum
creatinine, was partially but significantly preserved in Bax
knockout mice. The number of apoptotic cells was decreased
as was general tissue damage. Additionally, cisplatin-induced
cytochrome c release was attenuated in the Bax-deficient
mice. This significant decrease in apoptosis and in
cytochrome c release was also mirrored in primary cultures of
proximal tubular cells prepared from Bax knockout animals.
Collectively, our results provide compelling evidence for a
role of Bax and its related apoptotic pathway in cisplatin
nephrotoxicity.
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Cisplatin, a widely used chemotherapy drug, induces renal
injury, which limits its therapeutic efficacy.1,2 Nephrotoxicity
by cisplatin involves necrosis as well as apoptosis of renal
tubular cells. Mechanistically, tubular cell death under the
pathological condition may be initiated by multiple mechan-
isms.3–16 For apoptosis, both the intrinsic mitochondrial
pathway and the extrinsic death–receptor pathway have been
implicated.6,12,17–20 In addition, in vitro studies have further
suggested the involvement of ER stress related mechanisms.21
Using cultured renal cells, Lee et al. and Park et al. showed
Bax activation during cisplatin treatment, accompanied by
mitochondrial release of cytochrome c and apoptosis,
demonstrating the first evidence for the involvement of the
intrinsic pathway of apoptosis in cisplatin nephrotoxicity.
The observations were confirmed and further extended by
recent work.6,17,22 Despite the findings, these studies were all
conducted in in vitro systems of cell cultures. Whether and to
what extent Bax and related apoptotic pathway contribute to
in vivo cisplatin nephrotoxicity is unclear. Moreover, the
evidence collected from the earlier studies was correlative,
and definitive evidence for a role of Bax in tubular cell
apoptosis and renal injury during cisplatin nephrotoxicity
remains to be established.
In this study, we have examined and compared cisplatin
nephrotoxicity in wild-type and Bax-deficient mice and
tubular cells. We have demonstrated Bax induction and
activation in kidneys following cisplatin treatment of wild-
type animals. We have further shown that Bax-deficient mice
are more resistant to cisplatin injury than wild-type animals.
In primary cultures of proximal tubular cells, Bax deficiency
attenuates cytochrome c release and apoptosis during
cisplatin incubation. Together, this study has demonstrated
compelling evidence for a role of Bax and related apoptotic
pathway in cisplatin nephrotoxicity.
RESULTS
Bax expression and activation during cisplatin nephrotoxicity
in C57BL/6 mice
A single dose of cisplatin (30 mg/kg, intraperitoneally)
induced acute kidney injury in C57BL/6 mice, leading to
the loss of renal function. Three days after cisplatin injection,
the serum level of creatinine increased from 0.3 mg/dl to
3.1 mg/dl, and blood urea nitrogen (BUN) increased from
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B50 mg/dl to over 180 mg/dl. To examine changes in Bax, we
initially analyzed Bax expression under the pathological
condition. Immunoblotting of whole kidney lysates detected
an increase of Bax expression during cisplatin treatment
(Figure 1a). Bax was induced at day 1 (lane 2) and intensified
by day 3 (lane 4).
In normal healthy cells, Bax mainly resides in the cytosol.
Following activation, Bax translocates to mitochondria to
induce membrane permeabilization. Thus to detect Bax
activation, we analyzed Bax translocation or accumulation in
mitochondria. To this end, cytosolic and mitochondrial
fractions were isolated from kidney tissues for immunoblot
analysis of Bax. As shown in Figure 1b, in control tissues, Bax
was mainly detected in the cytosolic fraction (lane 1).
Following cisplatin treatment, cytosolic Bax increased to
some extent, whereas mitochondrial Bax had a marked
increase (lane 2), suggesting Bax accumulation and activation
in mitochondria under the pathological condition. We
further determined Bax activation by immunofluorescence
using an antibody that specifically recognized active Bax. As
expected, following the staining control renal cortical tissues
had a weak fluorescence background (Figure 1c: control).
After cisplatin treatment, active Bax immunofluorescence was
clearly shown in specific cells of cortical tissues. Noticeably,
Bax staining in these cells was in punctiform, suggesting
organellar or mitochondrial accumulation of Bax (Figure 1c:
cisplatin). Together these results demonstrate Bax induction
and activation during cisplatin nephrotoxicity in vivo.
Localization of Bax activation in renal tubular cells
To identify the cell type(s) that activated Bax, we co-stained
the kidney tissues for active Bax and tubular cell markers. For
this purpose, we used two fluorescein isothiocyanate (FITC)-
labeled lectins, Phaseolus Vulgaris Agglutinin (PHA) and
Peanut Agglutinin (PNA), which bind and stain proximal
and distal tubules respectively.23,24 PHA binds to proximal
tubular cells mainly at the brush border, whereas PNA binds
to the apical membrane of distal tubular cells. In renal cortex,
many cells were labeled by FITC-PHA (Figure 2a), whereas
fewer cells were labeled by FITC-PNA (Figure 2b). This was
expected, because the majority of renal tubules in the cortex
are proximal tubules. When the lectin staining images were
superimposed with Bax immunofluorescence, most of Bax
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Figure 1 | Bax expression and activation during cisplatin
nephrotoxicity. Wild-type C57BL/6 mice were injected with cisplatin
or saline as control. (a) Immunoblot of Bax and b-actin in whole tissue
extracts. Renal tissues were collected 0, 1, 2, or 3 days after cisplatin
injection for immunoblot analysis using an antibody for total Bax.
The blot was reprobed for b-actin to monitor protein loading and
transferring. (b) Immunoblot analysis of Bax in mitochondrial and
cytosolic fractions of renal tissues. Renal tissues were collected at day
3 of cisplatin treatment and fractionated into mitochondrial and
cytosolic fractions for immunoblot analysis using an antibody for
total Bax. (c) Immunofluorescence of active Bax in renal cortex. Renal
cortical tissues of control and 3 day cisplatin-treated mice were
processed for immunofluorescence using an antibody specific for
active Bax. The blots and immunofluorescence are representatives of
at least two separate experiments. The results show Bax expression,
mitochondrial accumulation, and activation during cisplatin
nephrotoxicity.
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Figure 2 | Bax activation in renal tubular cells during cisplatin
nephrotoxicity. Wild-type C57BL/6 mice were injected with cisplatin
to collect renal cortical tissues 3 days later. (c, d) The tissues were
processed for immunofluorescence of active Bax, followed by
staining with FITC-labeled (a) PHA or (b) PNA. (e, f) The images of Bax
immunofluorescence were superimposed with PHA or PNA staining
of the same tissues. Arrow: colocalization of active Bax and PHA
staining. Asterisk: colocalization of active Bax with PNA staining.
The results suggest that the majority of Bax active cells are in
proximal tubules.
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active cells overlapped with PHA staining (Figure 2e,
arrowed). Occasionally, we detected PNA-positive cells that
had active Bax, but the number was very limited (Figure 2f,
asterisk). The results suggest that cisplatin mainly induces
and activates Bax in cells of the proximal tubules.
Preservation of renal function in Bax-deficient mice during
cisplatin injury
To identify the role of Bax in cisplatin nephrotoxicity, we
compared wild-type (Baxþ /þ ) and Bax-deficient (Bax/)
mice for renal function during cisplatin treatment. We
routinely conducted genotyping to select Bax/ homozygote
mice for experiment. At the end of experiment, we confirmed
Bax deficiency in renal tissues of these animals by
immunoblot analysis (Figure 3a). Without cisplatin treat-
ment, Baxþ /þ and Bax/ mice showed similar basal levels
of BUN (B50 mg/dl) and serum creatinine (0.3–0.4 mg/dl)
(Figure 3b and c). Cisplatin treatment for 3 days induced
obvious increases in BUN (184 mg/dl) and serum creatinine
(3.1 mg/dl) in wild-type Baxþ /þ mice (Figure 3b and c: open
columns). The increases were significantly ameliorated in
Bax/ mice, which had a BUN value of 113 mg/dl and
serum creatinine of 1.4 mg/dl, suggesting a partial preserva-
tion of renal function in the gene knockout animals.
Cisplatin-induced renal tissue damage in wild-type and
Bax-deficient mice
We examined renal histology following hematoxylin and eosion
staining (Figure 4a). Without cisplatin treatment, Baxþ /þ and
Bax/ mice showed similar normal renal histology. Following
cisplatin injection, Baxþ /þ mice developed renal tissue
damage, which started from day 2 and became obvious at
day 3 (Figure 4a). The damage was characterized by tubular cell
lysis, complete loss of brush border, and sloughed debris in
tubular lumen space. During the observation period, the
damage was mainly concentrated in the outer stripe of outer
medulla and renal cortex. Compared with Baxþ /þ animals,
Bax/ mice showed less tubular damage and the majority of
the proximal tubules preserved their brush border, despite signs
of stress and injury including tubular dilation and distortion
(Figure 4a). We further determined the pathological scores of
the collected tissues. As shown in Figure 4B, the Baxþ /þ
animals had an injury score of 3.5, whereas Bax/ mice had a
score of 1.8.
Cisplatin-induced renal cell apoptosis in wild-type and
Bax-deficient mice
Bax is a critical pro-apoptotic molecule, which upon
activation accumulates in mitochondria to permeabilize the
outer membrane, leading to the release of apoptogenic
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Figure 3 | Loss of renal function during cisplatin treatment of
Bax-deficient and wild-type mice. Wild-type (Baxþ /þ ) and Bax-
deficient (Bax/) mice were injected with cisplatin or saline (control)
for 3 days. (a) Immunoblot analysis of Bax and b-actin in whole
kidney lysate to confirm Bax deficiency in Bax/ mice. (b) BUN. Data
are presented as mean7s.d., (nX8). (c) Serum creatinine
concentration. Data are presented as mean7s.d., (nX3). *Statistically
significant difference compared with control. #statistically significant
difference compared with cisplatin-treated wild-type group. The
results show an amelioration of cisplatin-induced renal failure in
Bax-deficient mice.
Bax(+/+)
Bax(–/–)
Bax(–/–)
Control Cisplatin
0
1
2
3
4
Bax(+/+)
Tu
bu
la
r d
am
ag
e
∗
Cisplatin
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
a
b
Figure 4 | Cisplatin-induced tissue damage in Bax-deficient and
wild-type mice. Wild-type (Baxþ /þ ) and Bax-deficient (Bax/) mice
were injected with cisplatin or saline (control) to collect renal cortical
tissues 3 days later. The tissues were fixed and paraffin-embedded for
hematoxylin and eosin (H&E) staining. (a) Representative images of
hematoxylin and eosin staining. Asterisks: lysed tubules.
(b) Pathological scores of tubular damage. Data are presented as
mean7s.d. (n¼ 5). *Statistically significant difference compared with
the wild-type (Baxþ /þ ) group. The results show lower tubular
damage in renal cortex of Bax-deficient mice.
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factors such as cytochrome c. To determine the effects of Bax-
deficiency on renal apoptosis during cisplatin nephrotoxicity,
we analyzed kidney tissues by terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL)
staining, which detects DNA cleavage in apoptotic cells (as
shown in Figure 5a). Regardless the Bax status, no TUNEL-
positive cells were shown in control renal tissues. Cisplatin
treatment led to significant amounts of TUNEL-positive cells
in Baxþ /þ kidneys of wild-type animals (Figure 5a,
arrowed). These cells were mainly detected in renal cortex
and outer medulla, and not in inner medulla (not shown).
Importantly, Bax/ mice had much fewer TUNEL-positive
cells in kidney tissues (Figure 5a). By counting the numbers
of TUNEL-positive cells, we further confirmed the significant
difference between wild-type (Baxþ /þ : 37 TUNEL-positive
cells/mm2) and Bax-deficient (Bax/: 15 TUNEL-positive
cells/mm2) tissues (Figure 5b).
To identify the origin(s) of the apoptotic cells, we
co-stained the wild-type renal tissues for TUNEL and PHA
or PNA. As shown in Figure 6a, the majority of TUNEL-
positive cells were shown in PHA-stained tubules (arrows).
We also detected some cells that had co-staining of TUNEL
and PNA (arrowheads), but the number of this type of cells
was relatively small. The results suggest the occurrence of
apoptosis in both proximal and distal tubules in this
experimental model. We further examined the colocaliza-
tion of TUNEL-positive cells with active Bax (Figure 6b).
For this purpose, active Bax was revealed by immunofluor-
escence using an antibody specific for active Bax. As shown in
Figure 6b, some cells were co-stained by both TUNEL assay
and active Bax immunofluorescence (arrowheads). Never-
theless, we also detected cells that were TUNEL-positive
but showed very weak or no active Bax (Box). There were
also cells that had active Bax but did not show clear TUNEL
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Figure 5 | Cisplatin-induced renal apoptosis in Bax-deficient and wild-type mice. Wild-type (Baxþ /þ ) and Bax-deficient (Bax/) mice
were injected with cisplatin or saline (control) to collect renal cortical tissues 3 days later. The tissues were fixed and paraffin-embedded for
TUNEL assay. (a) Representative images of TUNEL assay. Arrows: TUNEL-positive cells with condensed or fragmented nuclei. (b) Counting of
TUNEL-positive cells in renal cortical tissues. *Statistically significant difference compared with the wild-type group. Data are expressed as
mean7s.d. (nX10).
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staining (arrow). Analysis of the co-staining images indi-
cated that about 30–40% TUNEL-positive cells had active
Bax.
Cisplatin-induced cytochrome c release in renal tissues
of wild-type and Bax-deficient mice
We further examined cytochrome c release in renal tissues
during cisplatin treatment of Baxþ /þ and Bax/ animals.
To this end, renal cortical tissues were collected to isolate
cytosolic and mitochondrial fractions for immunoblot
analysis. In wild-type Baxþ /þ mice, there was a small yet
consistently detectable cytochrome c release after 2 days of
cisplatin treatment (Figure 7a: lane 2). At day 3, cytochrome c
released into the cytosolic fraction became obvious (Figure
7a: lane 3). Nevertheless, the released portion was o20% of
total cytochrome c and, as a result, mitochondrial cyto-
chrome c did not show an obvious decrease. Importantly,
cytochrome c release during cisplatin treatment was amelio-
rated in kidney tissues of Bax/ animals (Figure 7b).
Effects of Bax deficiency on cisplatin-induced apoptosis
in primary cultures of proximal tubular cells
We hypothesized that the observed resistance of Bax-deficient
animals to cisplatin nephrotoxicity was largely due to Bax
deficiency in proximal tubular cells. To test directly this
possibility, we isolated proximal tubular cells from wild-type
(Baxþ /þ ) and Bax-deficient (Bax/) mice. Primary cultures
of the cells were then treated with 50 mM cisplatin.
Representative cell morphology was shown in Figure 8a–d.
Apoptosis was minimal under control incubation, regardless
the presence or absence of Bax (not shown). Following
cisplatin treatment, some primary proximal tubular cells
developed typical apoptotic morphology, showing cellular
shrinkage, apoptotic body formation, and nuclear condensa-
tion and fragmentation (Figure 8a–d, arrows). Apoptosis was
obviously lower in Bax/ cells (Figure 8a–d). We further
quantified apoptosis by cell counting. As shown in Figure 8e,
under control conditions, the primary tubular cells had very
low apoptosis. Cisplatin treatment for 16 and 20 h induced
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Figure 6 | Localization of Bax activation and apoptosis in cisplatin-injured renal tissues. Wild-type C57BL/6 mice were injected with
cisplatin to collect renal cortical tissues at day 3. (a) The tissues were processed for TUNEL assay, followed by staining with FITC-labeled PHA or
PNA. The TUNEL images were superimposed with PHA or PNA staining of the same tissues to show the possible colocalization. Arrows:
localization of TUNEL-positive cells in PHA-stained tubules. Arrowheads: localization of TUNEL-positive cells in PNA-stained tubules. (b) The
tissues were processed for TUNEL assay and immunofluorescence of active Bax. The TUNEL image was superimposed with active Bax staining
to show colocalization. Arrowheads: colocalization of active Bax and TUNEL staining in the same cell. Box: TUNEL-positive cells with very weak
or no active Bax. Arrow: cell with active Bax but no TUNEL staining.
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about 20 and 30% apoptosis in Baxþ /þ tubular cells, but
only 5 and 10% in Bax/ cells (Figure 8e). Under the
experimental conditions, cisplatin did not induce significant
necrosis as shown by propidium iodide staining (not shown).
Cisplatin-induced cytochrome c release in wild-type and Bax-
deficient primary cultures of proximal tubular cells
We further determined cytochrome c release during cisplatin
treatment of primary cultures of Baxþ /þ and Bax/ tubular
cells. To this end, cells were fractionated into cytosolic and
organellar (mitochondrial) fractions for immunoblot analy-
sis. As shown in Figure 9a, without cisplatin treatment, both
Baxþ /þ and Bax/ cells had cytochrome c in mitochondria,
with very little cytochrome c in the cytosolic fraction (lanes 1,
2, 5, and 6). Following cisplatin incubation, significant
amounts of cytochrome c were detected in the cytosolic
fraction of Baxþ /þ cells, accompanied by obvious loss of
cytochrome c from the mitochondria fraction (lanes 3 and 4).
In Bax/ cells, cisplatin induced cytochrome c release (lanes
7, 8), but at a much lower level than Baxþ /þ cells. The
immunoblot results were confirmed by immunofluorescence
staining of cytochrome c (Figure 9b–m). In control cells,
cytochrome c immunofluorescence was exclusively mito-
chondrial, showing a perinuclear organellar staining (Figure
9b and d). Following cisplatin treatment, many Baxþ /þ cells
lost mitochondrial cytochrome c, resulting in a faint staining
in the cytosol (Figure 9c). The same cells showed apoptotic
morphology including nuclear fragmentation and condensa-
tion (Figure 9g and k, arrowed). Cytochrome c release was
also noticed in some cisplatin-treated Bax/ cells (Figure 9e
and m, arrowed), but the percentage was significantly lower.
Together the results support an important role of Bax in
mitochondrial membrane permeabilization, cytochrome c
release, and apoptosis during cisplatin nephrotoxicity.
DISCUSSION
Bax was implicated in cisplatin nephrotoxicity by previous
studies.6,17,18,22 However, those experiments were mainly
conducted in cultured cells and whether Bax has a role in
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Figure 7 | Cytochrome c release during cisplatin nephrotoxicity in
Bax-deficient and wild-type mice. (a) Cisplatin-induced cytochrome
c release in renal tissues of wild-type mice. After 0–3 days of cisplatin
treatment, renal cortical tissues were collected to isolate the
mitochondrial and cytosolic fractions for immunoblot analysis of
cytochrome c. (b) Cytochrome c release in renal cortical tissues
during cisplatin treatment of wild-type and Bax-deficient mice. Three
days after cisplatin or saline control injection, renal cortical tissues
were collected to isolate mitochondrial and cytosol fractions for
immunoblot analysis of cytochrome c. The blots are representatives
of three separate experiments. The results show cytochrome c release
during cisplatin nephrotoxicity, which is partially attenuated in
Bax-deficient mice.
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Figure 8 | Cisplatin-induced apoptosis in primary proximal
tubular cells isolated from wild-type and Bax-deficient mice.
Proximal tubular cells were isolated from wild-type (Baxþ /þ ) and
Bax-deficient (Bax/) mice and cultured for experiment. The cells
were incubated with or without 50mM cisplatin. (a–d) Representative
images of cell morphology after 20 h of cisplatin incubation. Cells
after cisplatin incubation were stained with Hoechst 33342. (a, b) Cell
and (c, d) nuclear morphology of the same fields were recorded by
phase-contrast and fluorescence microscopy, respectively. Arrows:
apoptotic cells showing cellular and nuclear condensation and
fragmentation. (e) Percentage of apoptosis evaluated by cell
counting. The cells with typical apoptotic morphology were counted
after control or cisplatin incubation for 16 or 20 h. Data are expressed
as mean7s.d. (nX6). *Statistically significant difference compared
with control. #Statistically significant difference compared with
cisplatin-treated wild-type group.
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cisplatin nephrotoxicity in vivo is unclear. Importantly, the
earlier evidence was correlative and circumstantial, and did
not establish the role of Bax by inhibitory approaches. Using
gene knockout mouse and primary culture models, the
current study has demonstrated the first compelling evidence
for the involvement of Bax in cisplatin nephrotoxicity.
The Bax-deficient mouse model was originally established
by Knudson et al.25 via targeted gene disruption.Bax/
homozygotes are viable with cell lineage-specific aberrations
in apoptosis, which are detected mainly in thymocytes, B cells
and male reproductive systems.25 The knockout model has
been used to identify a role for Bax in cell death during
tumorigenesis,26 spinal cord injury,27 and more recently
during myocardial ischemia–reperfusion.28 In our study,
Bax/ mice were used at the young adult age of 8–10 weeks.
The shape and size of the kidneys of these animals were
similar to those of the wild type. There were no noticeable
defects in renal function and structure in these animals either.
Unchallenged wild-type and Bax-deficient mice showed
similar basal levels of BUN and serum creatinine. The lack
of detectable abnormalities in kidneys of the Bax/ mice
justifies the feasibility of using this gene knockout model to
determine the involvement of Bax in the development of
renal pathology.
In wild-type C57BL/6 mice, cisplatin induced an early Bax
expression, starting from day 1 of treatment. At this time
point, renal injury shown by tissue damage, apoptosis, and
loss of renal function was not obvious (data not shown).29
Consistently, cytochrome c release was not detected (Figure 7)
until day 2 and 3, time points of Bax activation (Figure 1c).
The results suggest that the expressed Bax needs to be
activated to induce apoptosis. The temporal analysis supports
a role of Bax in tubular cell injury in this experimental model.
Active Bax was shown mainly in proximal tubules with
occasional occurrence in distal tubules (Figure 2). During
cisplatin nephrotoxicity, both proximal and distal tubules are
injured. Although work suggested distal tubules as the
primary site of apoptosis,30 more recent studies also showed
apoptosis in proximal tubules.9,20 As a result, primary and
transformed proximal tubular cells are commonly used to
study cisplatin-induced apoptosis as a critical pathogenic
event. Nevertheless these studies did not clearly identify the
origin(s) of apoptotic cells by using specific markers. We
stained the tissues with the lectins that are specific for
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Figure 9 | Cisplatin-induced cytochrome c release in primary cultures of proximal tubular cells isolated from wild-type and
Bax-deficient mice. Proximal tubular cells were isolated from wild-type (Baxþ /þ ) and Bax-deficient (Bax/) mice and cultured for experiment.
The cells were incubated with or without 50mM cisplatin for 20 h. (a) Immunoblot analysis of cytochrome c release. After control or cisplatin
incubation, the cells were fractionated into cytosolic and organellar (mitochondrial) fractions for immunoblot analysis of cytochrome c. Samples
from two separate experiments were analyzed on the same blot. (b–m) Immunofluorescence of cytochrome c. (b–e) Control and cisplatin-
treated cells were processed for immunofluorescence of cytochrome c and (f–i) then stained for nucleus with Hoechst 33342. (j–m) The
immunofluorescence and nuclear staining of the same cells were superimposed. Arrows: cells with cytochrome c in cytosol and apoptotic
nuclear morphology.
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proximal or distal tubules. The results show that many
apoptotic cells were stained with PHA, a proximal tubule-
binding lectin (Figure 6a). We also detected positive staining of
some apoptotic cells by PNA, a distal tubule-binding lectin. It
is suggested that apoptosis occurs in both proximal and distal
tubules in this experimental model. These observations
support the significance of Bax expression and activation in
proximal tubular cells during cisplatin nephrotoxicity.
Co-staining of active Bax and apoptosis (TUNEL)
indicated that 30–40% of apoptotic cells had Bax activation
(Figure 6b). Some TUNEL-positive cells did not show clear
active Bax staining. The straightforward explanation is that
Bax may be involved in apoptosis of the 30–40% cells but not
others. However, some of the apoptotic cells might have
entered late stage of apoptosis and thus have lost Bax due to
extensive proteolytic degradation. This possibility is sup-
ported by the quantitative comparison of apoptosis in wild-
type and Bax-deficient mice. As shown in Figure 5b,
apoptosis during cisplatin treatment was reduced from 37
in wild-type mice to 15 (TUNEL-positive cells/mm2) in Bax-
deficient mice, suggesting that Bax may be involved in 60%
(22/37) apoptosis in this experimental model. It is not
surprising that Bax deficiency did not completely block
apoptosis, because multiple pathways of apoptosis can be
activated by cisplatin in renal tubular cells.
In addition of apoptosis, necrotic tissue damage during
cisplatin nephrotoxicity was also suppressed in Bax-deficient
mice (Figure 4). This is an interesting observation because Bax
and related molecules are generally considered to be apoptotic.
However, it is noteworthy that these proteins, although
originally identified in apoptosis, may promote necrosis under
certain pathological conditions. Despite the distinct morpho-
logical differences, recent studies suggest that apoptosis and
necrosis may share some of the critical signaling events
including mitochondrial damage.31 It is speculated that by
damaging mitochondria, Bax and related molecules may also
be involved in necrotic cell death. Alternatively, some of the
necrotic cells may result from the lysis of apoptotic cells; by
reducing apoptosis, Bax deficiency may decrease this type of
‘secondary necrosis’. Our recent work showed that both
necrosis and apoptosis of tubular cells during renal ische-
mia–reperfusion were ameliorated in mice that were deficient
of Bid, another proapoptotic Bcl-2 family protein.32
The mechanisms of Bax expression and activation during
cisplatin nephrotoxicity are currently unclear. Nevertheless,
cisplatin activates p53 in renal tubular cells,5–7,13,17 which
reportedly is a transcriptional regulator of Bax expression.33
In p53-deficient mice, Bax expression during cisplatin
nephrotoxicity is ameliorated (Wei and Dong, unpublished
data). For Bax activation, our recent work suggests that p53-
upregulated modulator of apoptosis (PUMA-a) is induced in
a p53-dependent manner during cisplatin nephrotoxicity.
Following induction, PUMA-a translocates to mitochondria
to bind and neutralize Bcl-XL, freeing Bax for activation.6
This scenario emphasizes a role of PUMA-a in Bax
activation. However, it is noteworthy that, in addition to
protein interaction, Bax can also be regulated by phosphor-
ylation. In this direction, recent work by Kim et al.34 has
suggested the involvement of ERK in Bax regulation during
cisplatin incubation of opossum kidney cells. Further
investigations are needed to clarify the signaling pathways
that lead to Bax induction and activation during cisplatin
nephrotoxicity.
The inhibitory effects of Bax deficiency on cisplatin-
induced renal injury are substantial but not complete.
Apoptosis shown by TUNEL assay was suppressed to
B40% and tissue damage reduced to B50%. Consistently,
renal function measured as BUN and serum creatinine was
partially protected in these animals. These results suggest that
Bax is important to the development of cisplatin nephro-
toxicity, but it is not the single mediating factor. This
conclusion is consistent with previous studies, which suggest
the involvement of other apoptotic pathways in cisplatin
nephrotoxicity, including the death receptor-mediated ex-
trinsic pathway.19,20 In addition, other proapoptotic Bcl-2
proteins may have a redundant role of Bax. For example,
upon apoptosis induction, Bak may also oligomerize in
mitochondria to permeabilize the outer membrane, leading
to cytochrome c release and apoptosis.35
In conclusion, this study has demonstrated compelling
evidence for the involvement of Bax in cisplatin-induced
tubular cell apoptosis, acute kidney injury and renal failure.
Targeting Bax by pharmacological and genetic approaches
may offer a new therapeutic strategy for cisplatin nephro-
toxicity.
MATERIALS AND METHODS
Animals
Breeders of Bax-deficient and wild-type mice with C57BL/6
background were originally purchased from Jackson Laboratory
(Bar Harbor, ME, USA). Male Bax/ homogyzotes were infertile;
thus colonies of heterozygous Bax/þ were maintained. Bax/þ
animals were interbred to produce homozygous Bax/ mice for
experiments. The genotypes of the animals were determined by
polymerase chain reaction-based genotyping according to a
published protocol.36 In this study, male animals of 8–10 weeks
were used. As wild-type controls, both littermates and age/sex-
matched nonlittermate C57BL/6 mice were used.
Cisplatin treatment of animals
The animals were housed with a 12/12 h light–dark cycle, food and
water available ad libitum. Cisplatin was freshly prepared at 1 mg/ml
in saline and was administered by a single intraperitoneal injection
at a dose of 30 mg/kg as described previously.29 As control, a group
of animals was injected with a comparable volume of saline.
Analysis of renal function
Renal function was monitored by measuring serum creatinine and
BUN as described previously.29,32 Briefly, blood samples were
collected from the tail of the animals or at the time of killing.
After clotting at room temperature, serum was collected by
centrifugation. Creatinine was measured with a commercial kit
from Stanbio Laboratory (Boerne, TX, USA). BUN was measured
with a kit from Biotron Diagnostics Inc. (Hemet, CA, USA).
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Renal histology
Kidneys were harvested and fixed with 4% paraformaldehyde for
paraffin embedding. Paraffin-embedded tissues were sectioned at
4 mm for hematoxylin and eosin staining. Renal histology was
examined in a blinded fashion by an experimental pathologist.
Histological changes evaluated included the percentage of renal
tubules that displayed cell lysis, loss of brush border, and cast
formation. The development of tissue damage was scored as follows:
0, no damage; 1, o25%; 2, 25–50%; 3, 50–75%; 4, 475%. Pictures
of representative fields were also recorded.
TUNEL assay
Apoptosis in renal tissues was identified by TUNEL assay as shown
in our recent work.29,32 Renal tissues were fixed with 4%
paraformaldehyde, paraffin-embedded, and cut into 4-mm sections.
TUNEL assay was conducted using the in situ Cell Death Detection
kit from Roche Applied Science (Indianapolis, IN, USA), following
the manufacturer’s instruction. Briefly, tissue sections were depar-
affinized and permeabilized by 2 h of incubation at 651C in 0.1 M
sodium citrate (pH 6.0). The sections were then exposed to a
TUNEL reaction mixture containing terminal deoxynucleotidyl
transferase and nucleotides including FITC-labeled dUTP. Positive
staining was identified in cell nucleus with DNA breakage by
fluorescence microscopy.
Immunofluorescence
For staining of renal tissues, kidneys were collected and immediately
frozen in liquid nitrogen. Freshly frozen tissues were cryosectioned
at 7 mm and fixed with 4% paraformaldehyde for 20 min at room
temperature. The fixed samples were permeabilized with 1% Triton
X-100 and incubated for 1 h in a blocking buffer containing 2%
BSA, 0.2% nonfat milk, 0.8% Triton X-100, and 2% normal goat
serum. The samples were further incubated for 1 h with the primary
anti-active Bax antibody (Upstate Biotechnology, Lake Placid, NY,
USA). Finally, the slides were exposed to a Cy3-labelled goat anti-
rabbit secondary antibody (Chemicon, Temecula, CA, USA) for
examination by fluorescence microscopy. For immunofluorescence
analysis of cytochrome c in proximal tubular cells, the cells were
grown on collagen-coated coverslips and fixed with a modified
Zamboni’s fixative containing picric acid and 4% paraformaldehyde.
After blocking in 2% normal goat serum, the cells were incubated
with a mouse monoclonal anti-cytochrome c (BD Pharmingen, San
Jose, CA, USA), followed by exposure to Cy3-labelled goat anti-
mouse secondary antibody (Chemicon). The cells were finally
stained with 5 mg/ml Hoechst 33342 to examine nuclear morphology
by fluorescence microscopy.
Tissue staining with tubular cell markers
After immunofluorescence staining of active Bax, kidney tissues
were incubated again with the blocking buffer (see the above
section), followed by exposure to a FITC-labeled lectin. Two kinds of
lectins, PHA and PNA (Vector Laboratories, Burlingame, CA, USA),
were used in this study, which stain proximal tubules and distal
tubules, respectively.23,24 The double-stained tissues were examined
by confocal microscopy using a LSM 510 Zeiss microscope.
Preparation of cell or tissue lysate and fractions
To obtain whole kidney lysate, renal tissues were ground in liquid N2
and then immediately dissolved in 2% sodium dodecyl sulfate
buffer. Benzonase (VWR, West Chester, PA, USA) was added to
digest the genomic DNA. The insoluble part was further removed by
10 min of centrifugation at 15 000 g.
The mitochondrial and cytosolic fractions of kidney tissues were
collected as described by Weinberg et al.37 with some modifications.
Briefly, fresh or frozen kidney tissues were homogenized in a buffer
containing 0.27 M sucrose, 1mM EGTA, and 5 mM Tris–HCl (pH
7.4). The homogenates were centrifuged at 600 g for 10 min to
remove cell debris and nuclei. The supernatants were further
centrifuged at 10 000 g for 10 min to collect the mitochondrial
fraction in the pellets. The supernatant fractions were centrifuged
again at 100 000 g for 60 min to collect the cytosolic. The whole
isolation procedure was conducted at 41C.
Primary cultures of proximal tubular cells were fractionated into
cytosolic fraction and the membrane-bound organellar fraction by
using low concentrations of digitonin, which specifically permeabi-
lized the plasma membrane to release cell cytosol.6,17,38 Briefly, cells
were incubated with 0.05% digitonin in isotonic sucrose buffer (in
mM: 250 sucrose, 10 Hepes, 10 KCl, 1.5 MgCl2, 1 EDTA, and 1 EGTA;
pH 7.1) for 5 min at room temperature. The portion released by
digitonin was collected as the cytosolic fraction. Digitonin insoluble
part was further extracted with 2% sodium dodecyl sulfate to collect
the membrane bound fraction that contained mitochondria.
Primary proximal tubular cell culture
Proximal tubular cells were isolated for primary culture as described
by Nowak et al.39 and Zager et al.40 with minor modifications.
Briefly, immediately after the harvest of the kidneys, the renal cortex
part was collected and minced on an ice-cold plate. The minced
tissues were digested for 15 min with 0.75 mg/ml collagenase 4 at
371C in Hank’s solution containing 0.75 mg/ml trypsin inhibitor.
The digestion was stopped by mixing with ice-cold 10% horse
serum. Subsequently, the cells were washed with ice-cold Hanks’
solution and serum-free Dulbecco’s modified Eagle’s medium/F-12
medium. The proximal tubular cells were purified by 10 min of
centrifugation at 2000 g in 32% Percoll, 41C. The pellet was collected
and washed twice with ice-cold serum-free Dulbecco’s modified
Eagle’s medium/F-12 medium. Finally, the cells were plated into
collagen-coated dishes and cultured in Dulbecco’s modified Eagle’s
medium/F-12 medium supplemented with 5mg/ml transferrin, 5mg/ml
insulin, 0.05mM hydrocortisone, and 50mM vitamin c.
Cisplatin treatment of primary proximal tubular cells
The isolated cells were grown for 6–7 days and then plated at
0.3 106/35 mm dish for experiments. The next day, the cells were
incubated with 50 mM cisplatin in fresh culture medium. Cell
morphology was monitored by phase-contrast microscopy. Nuclear
morphology was examined by fluorescence microscopy following
Hoechst 33342 staining. Apoptosis was assessed by morphological
criteria including cellular shrinkage, formation of apoptotic bodies,
and condensation and fragmentation of nucleus. Cells with typical
apoptotic morphology were counted to quantify apoptosis.6,17
Immunoblot analysis
Immunoblotting was performed by standard procedures after
sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Briefly,
the blots were blocked with 5% fat-free milk and exposed to a
specific primary antibody. The blots were then exposed to the
horseradish-peroxidase-conjugated secondary antibody, and anti-
gens on the blots were revealed by using the enhanced chemilumi-
nescence kit (Pierce, Rockford, IL, USA).
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Statistics
Data were expressed as mean7s.d. Statistical differences between
two groups were determined by Student’s t-test with Microsoft Excel
2000. Po0.05 was considered significantly different.
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